Targeting Liver Epsins Ameliorates Dyslipidemia in Atherosclerosis.
Bo ZhuKrishan GuptaKui CuiBeibei WangMarina V MalovichkoXiangfei HanKathryn LiHao WuKulandai Samy ArulsamyBandana SinghJianing GaoScott WongDouglas B CowanDa-Zhi WangSudha BiddingerSanjay SrivastavaJinjun ShiKaifu ChenHong ChenPublished in: bioRxiv : the preprint server for biology (2024)
Liver epsins promote atherogenesis by mediating PCSK9-triggered degradation of LDLR, thus raising the circulating LDL-C levels. Targeting epsins in the liver may serve as a novel therapeutic strategy to treat atherosclerosis by suppression of PCSK9-mediated LDLR degradation.